Cargando…

Targeting CDK9 for treatment of colorectal cancer

Colorectal cancer (CRC) remains one of the most lethal human malignancies, and pursuit of new therapeutic targets for treatment has been a major research focus. Cyclin‐dependent kinase 9 (CDK9), which plays a crucial role in transcription, has emerged as a target for cancer treatment. CDKI‐73, one o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahaman, Muhammed H., Lam, Frankie, Zhong, Longjin, Teo, Theodosia, Adams, Julian, Yu, Mingfeng, Milne, Robert W., Pepper, Chris, Lokman, Noor A., Ricciardelli, Carmela, Oehler, Martin K., Wang, Shudong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763784/ https://www.ncbi.nlm.nih.gov/pubmed/31398271 http://dx.doi.org/10.1002/1878-0261.12559

Ejemplares similares

Chick Chorioallantoic Membrane (CAM) Assay as an In Vivo Model to Study the Effect of Newly Identified Molecules on Ovarian Cancer Invasion and Metastasis
por: Lokman, Noor A., et al.
Publicado: (2012)

S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer
por: Noye, Tannith M., et al.
Publicado: (2018)

A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer
por: Lee, Eunice, et al.
Publicado: (2020)

Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73
por: Lam, Frankie, et al.
Publicado: (2014)

Reducing the Invasiveness of Low- and High-Grade Endometrial Cancers in Both Primary Human Cancer Biopsies and Cell Lines by the Inhibition of Aquaporin-1 Channels
por: Khan, Sidra, et al.
Publicado: (2023)

Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer
por: Lokman, Noor A., et al.
Publicado: (2019)

Disabled-2 (DAB2): A Key Regulator of Anti- and Pro-Tumorigenic Pathways
por: Price, Zoe K., et al.
Publicado: (2022)

Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer
por: Lokman, Noor A., et al.
Publicado: (2021)

ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome
por: Wang, Wanqi, et al.
Publicado: (2021)

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine
por: Walsby, Elisabeth, et al.
Publicado: (2013)

Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer
por: Ricciardelli, Carmela, et al.
Publicado: (2013)

4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer
por: Lokman, Noor A., et al.
Publicado: (2019)

Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance
por: Price, Zoe K., et al.
Publicado: (2018)

Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities
por: Shao, Hao, et al.
Publicado: (2013)

Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis
por: Lokman, Noor A., et al.
Publicado: (2013)

Disabled-2: a protein up-regulated by high molecular weight hyaluronan has both tumor promoting and tumor suppressor roles in ovarian cancer
por: Price, Zoe K., et al.
Publicado: (2023)

Discovery of N,4-Di(1H-pyrazol-4-yl)pyrimidin-2-amine-Derived CDK2 Inhibitors as Potential Anticancer Agents: Design, Synthesis, and Evaluation
por: Fanta, Biruk Sintayehu, et al.
Publicado: (2023)

CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents
por: Anshabo, Abel Tesfaye, et al.
Publicado: (2021)

Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance
por: Ricciardelli, Carmela, et al.
Publicado: (2017)

Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype
por: Cheung, Janelle, et al.
Publicado: (2020)

Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer
por: Arentz, Georgia, et al.
Publicado: (2023)

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
por: Leung, Dilys, et al.
Publicado: (2022)

Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity
por: Hole, Alison J., et al.
Publicado: (2012)

Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis
por: Ween, Miranda P., et al.
Publicado: (2011)

Transforming Growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): A Matrix Protein with Dual Functions in Ovarian Cancer
por: Ween, Miranda P., et al.
Publicado: (2012)

Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations
por: Acland, Mitchell, et al.
Publicado: (2022)

Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug
por: Palasis, Kathryn A., et al.
Publicado: (2021)

Anti-Leukaemic Activity of Rilpivirine Is Mediated by Aurora A Kinase Inhibition
por: Islam, Saiful, et al.
Publicado: (2023)

Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery
por: Martin, Karina, et al.
Publicado: (2011)

An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia
por: Anshabo, Abel Tesfaye, et al.
Publicado: (2022)

Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer
por: Pyragius, Carmen E., et al.
Publicado: (2013)

Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
por: Macpherson, Anne M., et al.
Publicado: (2020)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Targeting Mnks for Cancer Therapy
por: Hou, Jinqiang, et al.
Publicado: (2012)

CDK3, CDK5 and CDK8 Proteins as Prognostic and Potential Biomarkers in Colorectal Cancer Patients
por: Wang, Dan, et al.
Publicado: (2022)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Targeting CDK9 for the Treatment of Glioblastoma
por: Ranjan, Alice, et al.
Publicado: (2021)

Combined In Silico and In Vitro Evidence Supporting an Aurora A Kinase Inhibitory Role of the Anti-Viral Drug Rilpivirine and an Anti-Proliferative Influence on Cancer Cells
por: Islam, Saiful, et al.
Publicado: (2022)

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor
por: Whittaker, Steven R., et al.
Publicado: (2018)

CDK2 Regulates HIV-1 Transcription by Phosphorylation of CDK9 on Serine 90
por: Breuer, Denitra, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_719guvrn9bgc43bvqhrlh0b8ru